The pathogenesis of neurodegenerative diseases prior to the onset of symptoms is generally not clear. The present study has employed a mouse model with a lack of the low-molecular-weight neurofilament subunit (NFL-/-), in which formation of protein aggregates occurs in neurons, to investigate glial cellular reactions in the lumbar cord segments of NFL-/- mice at ages from 1 to 6 months. Age-matched C57BL/6 mice serve as the control. Apparent neurofilament positive aggregates in the cytoplasm of motoneurons have been observed in NFL-/- mice. However, there were no noticeable changes in microglial numbers and GFAP staining of astrocytes. Unexpectedly, a downregulation in expression of complement receptor type 3 alpha subunit (CD11b) was detected in the spinal cord of NFL-/- mice, while there was no obvious difference between NFL-/- and C57BL/6 mice in the CD11b staining intensity of macrophages from livers and spleens. In addition, retardation in morphological transformation from activated to amoeboid microglia in response to sciatic nerve injury, differential expressions of some cytokines in the lumbar cord segments and induction of Iba-1 (ionized calcium-binding adaptor molecule-1) expression in microglia were observed in NFL-/- mice. Our results suggest not only the existence of an inhibitory niche for CD11b expression in microglia in the lumbar cord segments of NFL-/- mice but also differential microglial reactions between earlier and later stages of neuropathogenesis. Although the real cause for such inhibition is still unknown, this effect might play a particular role in the survival of the abnormal protein aggregate-bearing motoneurons in the early development stage of neurodegeneration in the NFL-/- mice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brainres.2006.07.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A robust evaluation of TDP-43, poly GP, cellular pathology and behavior in an AAV-C9ORF72 (GC) mouse model.
Acta Neuropathol Commun
December 2024
Brain Science Institute, Johns Hopkins University School of Medicine, Johns Hopkins University, 855 N. Wolfe St., Rangos 275, Baltimore, MD, 21205, USA.
The GC hexanucleotide repeat expansion in C9ORF72 is the major genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD). Despite considerable efforts, the development of mouse models of C9-ALS/FTD useful for therapeutic development has proven challenging due to the intricate interplay of genetic and molecular factors underlying this neurodegenerative disorder, in addition to species differences. This study presents a robust investigation of the cellular pathophysiology and behavioral outcomes in a previously described AAV mouse model of C9-ALS expressing 66 GC hexanucleotide repeats.
View Article and Find Full Text PDFCK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis.
Acta Neuropathol Commun
December 2024
Department of Neurosciences, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA, 92093-0624, USA.
Hyperphosphorylated TDP-43 aggregates in the cytoplasm of motor neurons is a neuropathological signature of amyotrophic lateral sclerosis (ALS). These aggregates have been proposed to possess a toxic disease driving role in ALS pathogenesis and progression, however, the contribution of phosphorylation to TDP-43 aggregation and ALS disease mechanisms remains poorly understood. We've previously shown that CK1δ and CK1ε phosphorylate TDP-43 at disease relevant sites, and that genetic reduction and chemical inhibition could reduce phosphorylated TDP-43 (pTDP-43) levels in cellular models.
View Article and Find Full Text PDFMyeloid cell-specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease.
Sci Transl Med
December 2024
German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Article Synopsis
- * In studies using a mouse model lacking the NPC1 protein in immune cells, researchers found significant changes in microglial lipid profiles, increased microglial activity, and symptoms resembling NPC disease, such as lifespan reduction and motor issues.
- * Monitoring translocator protein (TSPO) levels in the blood may be useful for assessing NPC disease progression and treatment response, as shown by changes in TSPO levels following a specific therapy that appeared beneficial for patients.
NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.
Front Aging Neurosci
September 2024
Janssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.
Article Synopsis
- Neuroinflammation plays a significant role in Alzheimer's disease, with the NLRP3 inflammasome being crucial in this process by promoting the maturation of inflammatory cytokines like IL-1β and IL-18 and influencing tau phosphorylation.
- This study utilized organotypic brain slice cultures and various mouse models to examine how tau seeds activate the NLRP3 inflammasome and how inhibiting NLRP3 might affect tau pathology.
- Results indicated that NLRP3 activation is linked to increased tau pathology and neurodegeneration, showcasing its potential as a therapeutic target in Alzheimer's disease treatment.
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
Transl Neurodegener
October 2024
Centre for Molecular Medicine and Therapeutics, Vancouver, BC, V5Z 4H4, Canada.
Article Synopsis
- Therapeutic strategies to lower mutant huntingtin (mHTT) levels show promise in reversing Huntington's disease (HD) symptoms in animal models, highlighting the need for effective biomarkers to evaluate these therapies.
- Neurofilament light chain (NfL) is a neurodegeneration biomarker that increases in the cerebrospinal fluid (CSF) and blood as HD progresses, but its role in assessing treatment efficacy remains unclear.
- In studies with YAC128 mice, NfL levels were elevated compared to control mice, and while lowering mHTT before disease symptoms had minimal impact on plasma NfL, it led to a significant reduction in CSF NfL, especially when treatment was started after disease onset.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!